基于双参数磁共振成像和临床参数预测模型用于改善初次活检男性的风险评估和活检选择
研究纳入876例初次活检且临床怀疑前列腺癌的男性,基于双参数MRI评分和临床参数构建预测模型以检测显著性前列腺癌。由双参数MRI评分、年龄、肿瘤分期和PSA密度定义的模型具有最高判别力(AUC 0.89),内部bootstrap验证校准良好,决策曲线分析净获益最大;采用20%活检风险阈值可使42%男性避免活检,漏诊仅7%的显著性癌症。
要点
- 双参数MRI评分联合年龄、肿瘤分期和PSA密度构建的模型AUC为0.89,判别力最高。
- 应用20%活检风险阈值可使42%男性避免活检,减少50%非显著性癌症诊断。
- 该阈值下仅7%的显著性癌症(Gleason分级组≥2)被漏诊。
核心结论
- 基于双参数MRI评分和临床参数的预测模型显著改善了初次活检男性的显著性前列腺癌风险分层,可用于临床决策和活检前咨询。
研究设计与样本
- 纳入876例初次活检且临床怀疑前列腺癌的男性(PSA<50 ng/mL,肿瘤分期<T3),行活检前前列腺双参数MRI(T2加权和弥散加权)后,所有男性接受10针标准活检,并对双参数MRI可疑病灶(可疑评分≥3)行MRI-经直肠超声融合靶向活检。
- 基于双参数MRI评分和临床参数(年龄、肿瘤分期、PSA水平、前列腺体积和PSA密度)构建预测模型以检测显著性前列腺癌(任何活检针Gleason分级组≥2),通过分析曲线下面积和决策曲线进行比较。
主要发现
- 总体中,350/876例男性(40%)检测到显著性前列腺癌,中位(四分位距)年龄和PSA水平分别为65岁(60-70)和7.3 ng/mL(5.5-10.6)。
- 由双参数MRI评分、年龄、肿瘤分期和PSA密度定义的模型具有最高判别力(曲线下面积0.89),内部bootstrap验证校准良好,决策曲线分析净获益最大。
- 应用20%活检风险阈值意味着42%的男性可避免活检,诊断的非显著性癌症减少50%,仅7%的显著性癌症(分级组≥2)被漏诊。
临床怎么用
- 基于双参数MRI评分和临床参数的预测模型可用于临床决策和活检前咨询男性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer risk prediction models and multiparametric magnetic resonance imaging (mpMRI) are used for individualised pre-biopsy risk assessment. However, biparametric MRI (bpMRI) has emerged as a simpler, more rapid MRI approach (fewer scan sequences, no intravenous contrast-media) to reduce costs and facilitate a more widespread clinical implementation. It is unknown how bpMRI and risk models perform conjointly. Therefore, the objective was to develop a predictive model for significant prostate cancer (sPCa) in biopsy-naive men based on bpMRI findings and clinical parameters. METHODS: Eight hundred and seventy-six biopsy-naive men with clinical suspicion of prostate cancer (prostate-specific antigen, <50 ng/mL; tumour stage, <T3) underwent pre-biopsy prostate bpMRI (T2-weighted and diffusion-weighted) followed by 10-core standard biopsies (all men) and MRI-transrectal ultrasound fusion targeted biopsies of bpMRI-suspicious lesions (suspicion score, ≥3). Prediction models based on bpMRI scores and clinical parameters (age, tumour stage, prostate-specific-antigen [PSA] level, prostatevolume, and PSAdensity) were created to detect sPCa (any biopsy-core with Gleason grade-group, ≥2) and compared by analysing the areas under the curves and decision curves. RESULTS: Overall, sPCa was detected in 350/876 men (40%) with median (inter-quartile range) age and PSA level of 65 years (60-70) and 7.3 ng/mL (5.5-10.6), respectively. The model defined by bpMRI scores, age, tumour stage, and PSAdensity had the highest discriminatory power (area under the curve, 0.89), showed good calibration on internal bootstrap validation, and resulted in the greatest net benefit on decision curve analysis. Applying a biopsy risk threshold of 20% meant that 42% of men could avoid a biopsy, 50% fewer insignificant cancers were diagnosed, and only 7% of significant cancers (grade-group, ≥2) were missed. CONCLUSIONS: A predictive model based on bpMRI scores and clinical parameters significantly improved risk stratification for sPCa in biopsy-naïve men and could be used for clinical decision-making and counselling men prior to prostate biopsies.
引用
- Boesen L, Thomsen FB, Nørgaard N, et al. A predictive model based on biparametric magnetic resonance imaging and clinical parameters for improved risk assessment and selection of biopsy-naïve men for prostate biopsies. Prostate Cancer Prostatic Dis. 2019. PMID: 30988407. doi:10.1038/s41391-019-0149-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。